Novo Nordisk, Viatris
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic.
Novo Nordisk CEO grilled for steep cost of Ozempic and other weight loss drugs
Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.
Sanders leads HELP Committee hearing with Novo Nordisk CEO on Ozempic and Wegovy prices
Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to examine why Novo Nordisk charges the American people the highest prices in the world for its lifesaving drugs,
Ozempic, Wegovy maker Novo Nordisk questioned over high cost of weight-loss drugs
U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North Carolina cut the weight-loss drugs from its state health plan.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according
WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...
FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears
Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...
Novo Nordisk: Mounting Challenges
Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...
Benefits Pro15d
'Stop ripping us off,' says Sen. Sanders, but Novo CEO blames PBMs for high Wegovy prices
Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...
USA Today17d
Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
Senators grilled the top executive of Novo Nordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does ...
Forbes29d
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...
US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...